Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression
Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression
复制标题
绞股蓝皂苷可改善小鼠非酒精性脂肪肝的肠道微生物群并减缓其进展
DOI：
10.1016/j.biopha.2019.109258
复制
发表时间：
2019-10-01
影响因子：
7.5
通讯作者：
Huang, Yuanpeng
中科院分区：
文献类型：
--
作者：
Huang, Xiaoqing;Chen, Wenfan;Huang, Yuanpeng
绞股蓝总皂苷（GP）是一种从植物中提取的传统中药（TCM），通常用于治疗代谢性疾病。本研究旨在探讨GP提取物对减轻非酒精性脂肪性肝病（NAFLD）的作用。本实验将C57 BL/6 J小鼠随机分为正常饮食对照组（ND）、高脂高胆固醇组（HFHC）和HFHC + GP组（GP）。HFHC组给予HFHC饲料加果糖饮用水喂养12周，诱导NAFLD动物模型，然后给予普通饮水直至实验结束。HFHC + GP组给予HFHC饲料和果糖饮用水喂养12周，结束时给予含GP的饮用水灌胃。每周测量小鼠体重。动物手术后，收集小鼠肝脏和血清样品。结果表明，GP给药减轻了NAFLD小鼠的体重，增强了对胰岛素抵抗（IR）的敏感性，降低了血清ALT、AST和TG水平。此外，GP治疗减轻了脂肪性肝炎，并下调了喂食HFHC饮食的小鼠中的ACC 1、PPAR γ、CD 36、APOC 3和MTTP水平。此外，GP治疗显著改善了NAFLD小鼠的肠道微生物群，并降低了粪便中厚壁菌门/拟杆菌门的相对丰度比。提示GP通过改善肠道菌群来减轻小鼠NAFLD。
Gypenosides (GP) are a type of traditional Chinese medicine (TCM) extracted from plants and commonly applied for treatment of metabolic diseases. This study aims to explore the effects of GP extracts on alleviating nonalcoholic fatty liver disease (NAFLD). In this experiment, C57BL/6 J mice were randomly assigned into normal diet control (ND), HFHC (high-fat and high-cholesterol) and HFHC + GP (GP) groups. Mice in HFHC group were fed HFHC diet combined with fructose drinking water for 12 weeks to induce the animal model of NAFLD, followed by ordinary drinking water until the end of the experiment. In the HFHC + GP group, mice were fed HFHC diet combined with fructose drinking water for 12 weeks, followed by GP-containing drinking water fill the end. Mouse body weight was measured weekly. After animal procedures, mouse liver and serum samples were collected. It is shown that GP administration reduced body weight, enhanced the sensitivity to insulin resistance (IR) and decreased serum levels of ALT, AST and TG in NAFLD mice. In addition, GP treatment alleviated steatohepatitis, and downregulated ACC1, PPAR gamma, CD36, APOC3 and MTTP levels in mice fed with HFHC diet. Furthermore, GP treatment markedly improved intestinal microbiota, and reduced relative abundance ratio of Firmicutes / Bacteroidetes in the feces of NAFLD mice. Our results suggested that GP alleviated NAFLD in mice through improving intestinal microbiota.